Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma

被引:5
|
作者
Yabuno, Akira [1 ]
Matsushita, Hirokazu [2 ]
Hamano, Tetsutaro [1 ]
Tan, Tuan Zea [3 ]
Shintani, Daisuke [1 ]
Fujieda, Nao [2 ]
Tan, David S. P. [3 ,4 ,5 ]
Huang, Ruby Yun-Ju [6 ]
Fujiwara, Keiichi [1 ]
Kakimi, Kazuhiro [2 ]
Hasegawa, Kosei [1 ]
机构
[1] Saitama Med Univ, Int Med Ctr, Dept Gynecol Oncol, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan
[2] Univ Tokyo Hosp, Dept Immunotherapeut, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan
[3] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore
[4] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
[5] Natl Univ Singapore Hosp, Natl Univ Canc Inst, Singapore, Singapore
[6] Natl Taiwan Univ, Sch Med, Coll Med, Taipei, Taiwan
关键词
DISTINCT-HISTOLOGIC-TYPE; POOR-PROGNOSIS; T-CELLS; CANCER; CHEMOTHERAPY; RESISTANCE; SURVIVAL;
D O I
10.1038/s41598-020-75536-1
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Serum cytokine and chemokine networks may reflect the complex systemic immunological interactions in cancer patients. Studying groups of cytokines and their networks may help to understand their clinical biology. A total of 178 cases of ovarian cancer were analyzed in this study, including 73 high-grade serous (HGSC), 66 clear cell (CCC) and 39 endometrioid carcinomas. Suspension cytokine arrays were performed with the patients' sera taken before the primary surgery. Associations between each cytokine and clinicopathological factors were analyzed in all patients using multivariate linear regression models, and cluster analyses were performed for each histotype. In the multivariate analyses, twelve of 27 cytokines were correlated with histotypes. Cluster analyses in each histotype revealed 2 cytokine signatures S1 and S2 in HGSC, and similarly C1 and C2 in CCC. Twenty-two of 27 cytokines were commonly clustered in HGSC and CCC. Signature S1 and C1 included IL-2,6,8,15, chemokines and angiogenic factors, whereas signature S2 and C2 included IL-4,5,9,10,13, TNF-alpha and G-CSF. Four subgroups based on a high or low level for each signature were identified, and this cluster-based classification demonstrated significantly different progression-free and overall survivals for CCC patients (P=0.00097 and P=0.017).
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma
    Huang, Huei-Jean
    Yang, Lan-Yan
    Tung, Hsiu-Jung
    Ku, Fei-Chun
    Wu, Ren-Chin
    Tang, Yun-Hsin
    Chang, Wei-Yang
    Jung, Shih-Ming
    Wang, Chun-Chieh
    Lin, Cheng-Tao
    Liu, Feng-Yuan
    Lin, Gigin
    Chen, Min-Yu
    Chou, Hung-Hsueh
    Chang, Ting-Chang
    Chao, Angel
    Lai, Chyong-Huey
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (04) : 793 - 804
  • [22] Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes
    Bolton, Kelly L.
    Chen, Denise
    Fuente, Rosario Corona de la
    Fu, Zhuxuan
    Murali, Rajmohan
    Kobel, Martin
    Tazi, Yanis
    Cunningham, Julie M.
    Chan, Irenaeus C. C.
    Wiley, Brian J.
    Moukarzel, Lea A.
    Winham, Stacey J.
    Armasu, Sebastian M.
    Lester, Jenny
    Elishaev, Esther
    Laslavic, Angela
    Kennedy, Catherine J.
    Piskorz, Anna
    Sekowska, Magdalena
    Brand, Alison H.
    Chiew, Yoke-Eng
    Pharoah, Paul
    Elias, Kevin M.
    Drapkin, Ronny
    Churchman, Michael
    Gourley, Charlie
    DeFazio, Ann
    Karlan, Beth
    Brenton, James D.
    Weigelt, Britta
    Anglesio, Michael S.
    Huntsman, David
    Gayther, Simon
    Konner, Jason
    Modugno, Francesmary
    Lawrenson, Kate
    Goode, Ellen L.
    Papaemmanuil, Elli
    CLINICAL CANCER RESEARCH, 2022, 28 (22) : 4947 - 4956
  • [23] Identification of novel therapeutically targetable fusion transcripts in ovarian clear cell carcinoma
    Yoshihara, Kosuke
    Mori, Yutaro
    Yamawaki, Kaoru
    Ishiguro, Tatsuya
    Enomoto, Takayuki
    CANCER SCIENCE, 2018, 109 : 308 - 308
  • [24] Serum cytokine arrays reveal different cytokine profiles as prognostic factors for overall survival in patients with ovarian high-grade serous and clear cell carcinoma
    Yabuno, A.
    Matsushita, H.
    Fujieda, N.
    Shintani, D.
    Ogasawara, A.
    Fujiwara, K.
    Kakimi, K.
    Hasegawa, K.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 86 - 86
  • [25] Identification of gene mutations in ovarian clear cell carcinoma by next generation sequencing
    Tanaka, N.
    Maru, Y.
    Suzuka, K.
    Ijiri, M.
    Hippo, Y.
    Nagase, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 840 - 840
  • [26] IDENTIFICATION OF POTENTIAL REGULATORY VARIANTS FOR THE DEVELOPMENT OF OVARIAN CLEAR CELL CARCINOMA.
    Kim, J.
    Jeong, S. Y.
    Kim, M. S.
    Paik, E. S.
    Kim, T. J.
    Lee, J. W.
    Kim, B. G.
    Bae, D. S.
    Choi, C. H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 170 - 170
  • [27] Identification of Intranuclear Inclusions is Useful for the Cytological Diagnosis of Ovarian Clear Cell Carcinoma
    Naka, Masaki
    Ohishi, Yoshihiro
    Kaku, Tsunehisa
    Watanabe, Sumiko
    Tamiya, Sadafumi
    Ookubo, Fumihiko
    Kato, Kiyoko
    Oda, Yoshinao
    Sugishima, Setsuo
    DIAGNOSTIC CYTOPATHOLOGY, 2015, 43 (11) : 879 - 884
  • [28] Identification of hub genes associated with outcome of clear cell renal cell carcinoma
    Li, Rengui
    Wang, Lei
    Wang, Xiao
    Geng, Rong-Xin
    Li, Ning
    Liu, Xiu-Heng
    ONCOLOGY LETTERS, 2020, 19 (04) : 2846 - 2860
  • [29] IDENTIFICATION OF A microRNA SIGNATURE ASSOCIATED WITH METASTASIS IN CLEAR CELL RENAL CELL CARCINOMA
    Heinzelmann, J.
    Henning, B.
    Sanjmyatav, J.
    Posorski, N.
    Steiner, T.
    Wunderlich, H.
    Junker, K.
    CELLULAR ONCOLOGY, 2010, 32 (03) : 191 - 191
  • [30] Identification of genomic alterations associated with metastasis in clear cell renal cell carcinoma
    Thodima, Venkata J.
    Gowrishankar, Banumathy
    Molina, Ana
    Georges, Murielle
    Chaganti, R. S. K.
    Motzer, Robert J.
    Houldsworth, Jane
    CANCER RESEARCH, 2014, 74 (19)